Co-expression of CMTM6 and PD-L1: a novel prognostic indicator of gastric cancer

Co-expression of CMTM6 and PD-L1: a novel prognostic indicator of gastric cancer

Abstract Background CKLF Like MARVEL Transmembrane Domain Containing 6 (CMTM6) is involved in the epigenetic regulation of genes and tumorigenesis. Programmed cell death ligand 1 (PD-L1) is closely related to the prognosis of some human cancers. CMTM6 is a key regulator of PD-L1 in many cancers. The...

Full description

Bibliographic Details
Main Authors:	Chao Zhang, Shutao Zhao, Xudong Wang
Format:	Article
Language:	English
Published:	BMC 2021-01-01
Series:	Cancer Cell International
Subjects:	Gastric cancer CMTM6 PD-L1 Survival
Online Access:	https://doi.org/10.1186/s12935-020-01734-6

Similar Items

Co-Expression with Membrane CMTM6/4 on Tumor Epithelium Enhances the Prediction Value of PD-L1 on Anti-PD-1/L1 Therapeutic Efficacy in Gastric Adenocarcinoma
by: Ziqi Wang, et al.
Published: (2021-10-01)

CMTM6 significantly relates to PD-L1 and predicts the prognosis of gastric cancer patients
by: Xin Li, et al.
Published: (2020-08-01)

Expression Analysis of Canine CMTM6 and CMTM4 as Potential Regulators of the PD-L1 Protein in Canine Cancers
by: Hiroto Takeuchi, et al.
Published: (2020-06-01)

CMTM6 and CMTM4 as two novel regulators of PD-L1 modulate the tumor microenvironment
by: Tong Zhang, et al.
Published: (2022-07-01)

Quantitative analysis of CMTM6 expression in tumor microenvironment in metastatic melanoma and association with outcome on immunotherapy
by: Sandra Martinez-Morilla, et al.
Published: (2021-01-01)

Increased CMTM6 can predict the clinical response to PD-1 inhibitors in non-small cell lung cancer patients
by: Young Wha Koh, et al.
Published: (2019-10-01)

Prognostic Implications of Pan-Cancer CMTM6 Expression and Its Relationship with the Immune Microenvironment
by: Yanbin Zhao, et al.
Published: (2021-01-01)

Prognostic significance and immune characteristics of CMTM4 in hepatocellular carcinoma
by: Shengkui Tan, et al.
Published: (2022-08-01)

Overexpressed CMTM6 Improves Prognosis and Associated With Immune Infiltrates of Ovarian Cancer
by: Bo Yin, et al.
Published: (2022-01-01)

CMTM6 promotes migration, invasion, and EMT by interacting with and stabilizing vimentin in hepatocellular carcinoma cells
by: Xiaoting Huang, et al.
Published: (2021-03-01)

Expression and clinical significance of CMTM1 in hepatocellular carcinoma
by: Song Xin, et al.
Published: (2021-01-01)

CMTM6 overexpression confers trastuzumab resistance in HER2-positive breast cancer
by: Fei Xing, et al.
Published: (2023-01-01)

CMTM6 is highly expressed in lung adenocarcinoma and can be used as a biomarker of a poor diagnosis
by: Daqi Jia, et al.
Published: (2023-01-01)

CMTM Family and Gastrointestinal Tract Cancers: A Comprehensive Review
by: Li J, et al.
Published: (2022-04-01)

Epithelial to Mesenchymal Transition Regulates Surface PD-L1 via CMTM6 and CMTM7 Induction in Breast Cancer
by: Malina Xiao, et al.
Published: (2021-03-01)

Loss of CMTM6 promotes DNA damage-induced cellular senescence and antitumor immunity
by: Hanfeng Wang, et al.
Published: (2022-12-01)

Differential Expression of CKLF-like MARVEL Transmembrane Domain-Containing Protein 6 and Programmed Cell Death Ligand 1 as Prognostic Biomarkers in Upper Tract Urothelial Carcinoma
by: Said Kdimati, et al.
Published: (2024-03-01)

Current Opinions on the Relationship Between CMTM Family and Hepatocellular Carcinoma
by: Pei Y, et al.
Published: (2023-08-01)

CMTM3 protects the gastric epithelial cells from apoptosis and promotes IL-8 by stabilizing NEMO during Helicobacter pylori infection
by: Jing Zhang, et al.
Published: (2023-02-01)

Identification of prognostic biomarkers in the CMTM family genes of human ovarian cancer through bioinformatics analysis and experimental verification
by: Mengjun Zhang, et al.
Published: (2022-08-01)

Overexpression of CMTM7 inhibits cell growth and migration in liver cancer
by: Zi‐Ming Huang, et al.
Published: (2019-06-01)

CMTM7 recognizes an immune-hot tumor microenvironment and predicts therapeutic response of immunotherapy in breast cancer well
by: Xingyu Jiang, et al.
Published: (2022-12-01)

Expressions of ZNF436, β-catenin, EGFR, and CMTM5 in breast cancer and their clinical significances
by: Zhi Chen, et al.
Published: (2021-01-01)

Identifying Predictive Biomarkers for Head and Neck Squamous Cell Carcinoma Response
by: Anne-Sophie Becker, et al.
Published: (2023-11-01)

MicroRNA-205 inhibits renal cells apoptosis via targeting CMTM4
by: Hongxia Zhang, et al.
Published: (2015-10-01)

Prognostic Role of PD-1 and PD-L1 Expression in Gastric Cancer Patients: A Meta-analysis
by: WANG Yufeng, et al.
Published: (2020-05-01)

CMTM family proteins 1–8: roles in cancer biological processes and potential clinical value
by: Jie Wu, et al.
Published: (2020-08-01)

Chemokine-like factor-like MARVEL transmembrane domain containing 6: Bioinformatics and experiments in vitro analyze in glioblastoma multiforme
by: Haining Meng, et al.
Published: (2023-01-01)

Prognostic Significance of PD-L1 Expression in Gastric Cancer Patients with Peritoneal Metastasis
by: Xiao-Jiang Chen, et al.
Published: (2023-07-01)

CMTM5 is downregulated and suppresses tumour growth in hepatocellular carcinoma through regulating PI3K-AKT signalling
by: Gang Xu, et al.
Published: (2017-11-01)

CMTM7 as a novel molecule of ATG14L-Beclin1-VPS34 complex enhances autophagy by Rab5 to regulate tumorigenicity
by: Baocai Liu, et al.
Published: (2021-07-01)

CMTM Family Genes Affect Prognosis and Modulate Immunocytes Infiltration in Grade II/III Glioma Patients by Influencing the Tumor Immune Landscape and Activating Associated Immunosuppressing Pathways
by: Zeyu Wang, et al.
Published: (2022-02-01)

CMTM3 suppresses bone formation and osteogenic differentiation of mesenchymal stem cells through inhibiting Erk1/2 and RUNX2 pathways
by: Dongwei Fan, et al.
Published: (2021-11-01)

Loss of the Novel Myelin Protein CMTM5 in Multiple Sclerosis Lesions and Its Involvement in Oligodendroglial Stress Responses
by: Jiangshan Zhan, et al.
Published: (2023-08-01)

The heterogeneity of PD-L1 protein in gastric cancer: expression and distribution characteristics
by: Yuejun Wang, et al.
Published: (2022-12-01)

Relationship between the expressions of PD-L1 and tumour-associated fibroblasts in gastric cancer
by: Linsong Mu, et al.
Published: (2019-12-01)

CMTM7 inhibits breast cancer progression by regulating Wnt/β-catenin signaling
by: Zhao-Hui Chen, et al.
Published: (2023-02-01)

G6PD-NF-κB-HGF Signal in Gastric Cancer-Associated Mesenchymal Stem Cells Promotes the Proliferation and Metastasis of Gastric Cancer Cells by Upregulating the Expression of HK2
by: Bin Chen, et al.
Published: (2021-02-01)

Identification and validation of stromal-tumor microenvironment-based subtypes tightly associated with PD-1/PD-L1 immunotherapy and outcomes in patients with gastric cancer
by: Qianqian Ren, et al.
Published: (2020-03-01)

Autophagy inhibition enhances PD-L1 expression in gastric cancer
by: Xiaojuan Wang, et al.
Published: (2019-03-01)